{"created":"2023-05-15T14:48:00.837990+00:00","id":65805,"links":{},"metadata":{"_buckets":{"deposit":"6cbc123d-7cfb-474c-b6fb-20803acc3569"},"_deposit":{"created_by":1,"id":"65805","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"65805"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00065805","sets":["10:29"]},"author_link":["648216","648218","648217","648213","648215","648214","648220","648219"],"item_10005_date_7":{"attribute_name":"発表年月日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2015-11-06","subitem_date_issued_type":"Issued"}]},"item_10005_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"【Objective】Astatine 211 (211At, T1/2=7.21h) is one of the attractive alpha emitter as it belongs to the same family as iodine, and the application into radioimmunotherapy (211At-RIT) is expected. We evaluated the biological effects of 211At-RIT both in vitro and in vivo.【Methods】211At was labeled with trastuzumab, anti-HER2 monoclonal antibody, using N-succinimidyl-3-(trimethylstannyl)benzoate. The in vitro cytotoxicity was evaluated by cell growth assay using a human metastatic gastric cancer cell line overexpressing HER2 protein. 211At-labeled trastuzumab, 0.5-2.5 MBq, was injected into mice bearing gastric cancer xenografts to determine the anti-tumor effect in vivo.【Results】211At-labeled trastuzumab showed significant cytotoxicity in vitro and suppressed tumor growth in vivo.【Conclusion】211At-RIT could be an effective treatment to HER2 overexpressing gastric cancer. ","subitem_description_type":"Abstract"}]},"item_10005_description_6":{"attribute_name":"会議概要（会議名, 開催地, 会期, 主催者等）","attribute_value_mlt":[{"subitem_description":"第55回日本核医学会学術総会","subitem_description_type":"Other"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"李, 惠子"}],"nameIdentifiers":[{"nameIdentifier":"648213","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"長谷川, 純崇"}],"nameIdentifiers":[{"nameIdentifier":"648214","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"永津, 弘太郎"}],"nameIdentifiers":[{"nameIdentifier":"648215","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"佐賀, 恒夫"}],"nameIdentifiers":[{"nameIdentifier":"648216","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"李 惠子","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"648217","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"長谷川 純崇","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"648218","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"永津 弘太郎","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"648219","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"佐賀 恒夫","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"648220","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"conference object","resourceuri":"http://purl.org/coar/resource_type/c_c94f"}]},"item_title":"α線放出核種211Atを用いた放射免疫療法 ","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"α線放出核種211Atを用いた放射免疫療法 "}]},"item_type_id":"10005","owner":"1","path":["29"],"pubdate":{"attribute_name":"公開日","attribute_value":"2015-11-11"},"publish_date":"2015-11-11","publish_status":"0","recid":"65805","relation_version_is_last":true,"title":["α線放出核種211Atを用いた放射免疫療法 "],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T20:56:03.814456+00:00"}